Skip to main content
. Author manuscript; available in PMC: 2017 Jan 15.
Published in final edited form as: J Immunol. 2015 Dec 9;196(2):915–923. doi: 10.4049/jimmunol.1500729

Figure 1. Antitumor effect of DFMO is dependent on CD8+ T cells.

Figure 1

B16F10 (A, B) or B16-SIY (C) cells were injected s.c. into WT (A, C) or Rag−/− C57BL/6 mice (B) (5 mice per group). DFMO was administered as a 1% solution in drinking dH2O to mice starting 1 day after tumor injection. The mean DFMO consumption of mice was approximately 1.5 g/kg/day. Mice fed with dH2O without DFMO were used as controls (5 mice per group). (C) Depletion of CD8+ T cells was achieved by twice-weekly i.p. injection of depleting mAb clone 53.6.7 (anti-CD8α, 200 μg), starting 1 day prior to tumor challenge. Tumor volumes were measured every 2 or 3 days (5 mice per group). Data (mean ± SEM) are representative of at least 3 independent experiments. *, p< 0.05; **, p<0.01.